EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

This approval enables the use of Enhertu as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have previously ...

Breast cancer remains the most common cancer among women globally, and Germany stands at the forefront of offering advanced and effective treatment options. Through a combination of high medical ...